State Key Laboratory of Genetic Engineering and Collaborative Innovation Center for Genetics and Development, School of Life Sciences, Fudan University, Shanghai, China.
Fudan University Taizhou Institute of Health Sciences, Taizhou, China.
Int J Epidemiol. 2021 Mar 3;50(1):128-142. doi: 10.1093/ije/dyaa196.
Predictions of primary liver cancer (PLC) incidence rates and case numbers are critical to understand and plan for PLC disease burden.
Data on PLC incidence rates and case numbers from 1990 to 2017 were retrieved from the Global Burden of Disease database. The estimated average percentage change (EAPC) was calculated to quantify the trends of PLC age-standardized incidence rates (ASRs). Bayesian age-period-cohort models were constructed to project PLC incidence rates and case numbers through 2030.
Globally, the PLC case number doubled from 472 300 in 1990 to 953 100 in 2017. The case number will further increase to 1 571 200 in 2030, and the ASR will increase from 11.80 per 100 000 in 2018 to 14.08 per 100 000 in 2030. The most pronounced increases are observed in people afflicted by non-alcoholic steatohepatitis (NASH) and in older people. The trends of PLC incidence rates between 1990 and 2030 are heterogeneous among countries and can be summarized as five scenarios: (i) 46 countries that have and will continue to experience a persistent increase (e.g. Australia); (ii) 21 countries that experienced an initial decrease (or remained stable) but are predicted to increase (e.g. China); (iii) 7 countries that experienced an initial increase but are predicted to remain stable (e.g. USA); (iv) 29 countries that experienced an initial increase but are predicted to decrease (e.g. Egypt); and (v) 82 countries that have and will continue to experience a persistent decrease (e.g. Japan).
PLC incidence rates and case numbers are anticipated to increase at the global level through 2030. The increases in people afflicted by NASH and among older people suggest a dearth of attention for these populations in current prevention strategies and highlight their priority in future schedules for global control of PLC.
原发性肝癌(PLC)发病率和病例数的预测对于了解和规划 PLC 疾病负担至关重要。
从全球疾病负担数据库中检索了 1990 年至 2017 年 PLC 发病率和病例数的数据。计算了估计的平均百分比变化(EAPC),以量化 PLC 年龄标准化发病率(ASR)的趋势。构建了贝叶斯年龄-时期-队列模型,以预测 2030 年 PLC 的发病率和病例数。
全球 PLC 病例数从 1990 年的 472300 例增加到 2017 年的 953100 例。到 2030 年,病例数将进一步增加到 1571200 例,ASR 将从 2018 年的 11.80/10 万增加到 2030 年的 14.08/10 万。发病率增加最显著的是患有非酒精性脂肪性肝炎(NASH)和老年人。1990 年至 2030 年期间,PLC 发病率趋势在各国之间存在异质性,可以总结为五个情景:(i)46 个国家已经并将继续经历持续增加(例如澳大利亚);(ii)21 个国家经历了初始下降(或保持稳定)但预计会增加(例如中国);(iii)7 个国家经历了初始增加但预计保持稳定(例如美国);(iv)29 个国家经历了初始增加但预计会下降(例如埃及);和(v)82 个国家已经并将继续经历持续下降(例如日本)。
预计到 2030 年,全球 PLC 的发病率和病例数将增加。NASH 患者和老年人发病率的增加表明,目前预防策略对这些人群的关注不足,突出了在未来全球 PLC 控制计划中优先考虑这些人群的必要性。